Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (22)

2024

  1. Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles

    Gene Therapy, Vol. 31, Núm. 9-10, pp. 455-466

  2. Development and characterization of a non-human primate model of disseminated synucleinopathy

    Frontiers in Neuroanatomy, Vol. 18

2023

  1. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  2. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

2022

  1. Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives

    Biomedicines, Vol. 10, Núm. 4

2021

  1. Adeno-associated viral vectors as versatile tools for parkinson’s research, both for disease modeling purposes and for therapeutic uses

    International Journal of Molecular Sciences, Vol. 22, Núm. 12

  2. Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

2020

  1. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  2. Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum

    Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42

2019

  1. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

2018

  1. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

  2. Glucocerebrosidase expression patterns in the non-human primate brain

    Brain Structure and Function, Vol. 223, Núm. 1, pp. 343-355

2017

  1. Adeno-associated viral vectors serotype 8 for cell-specific delivery of therapeutic genes in the central nervous system

    Frontiers in Neuroanatomy, Vol. 11

  2. Neurochemical evidence supporting dopamine D1–D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation

    Brain Structure and Function, Vol. 222, Núm. 4, pp. 1767-1784

2015

  1. Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism

    Brain Structure and Function, Vol. 220, Núm. 5, pp. 2721-2738

  2. Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia

    Molecular Neurobiology, Vol. 52, Núm. 3, pp. 1408-1420

2014

  1. Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques

    Frontiers in Neuroanatomy, Vol. 8, Núm. DEC

  2. L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus

    Neuropharmacology, Vol. 79, pp. 90-100

  3. Phosphodiesterase inhibition in cognitive decline

    Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573

2013

  1. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD

    Neuropharmacology, Vol. 64, pp. 114-123